SG10201606949QA - Immunosuppressive composition for use in treating immunological disorders - Google Patents
Immunosuppressive composition for use in treating immunological disordersInfo
- Publication number
- SG10201606949QA SG10201606949QA SG10201606949QA SG10201606949QA SG10201606949QA SG 10201606949Q A SG10201606949Q A SG 10201606949QA SG 10201606949Q A SG10201606949Q A SG 10201606949QA SG 10201606949Q A SG10201606949Q A SG 10201606949QA SG 10201606949Q A SG10201606949Q A SG 10201606949QA
- Authority
- SG
- Singapore
- Prior art keywords
- immunological disorders
- treating immunological
- immunosuppressive composition
- immunosuppressive
- composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/195—Chemokines, e.g. RANTES
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2066—IL-10
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
Priority Applications (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SG10201606949QA SG10201606949QA (en) | 2016-08-19 | 2016-08-19 | Immunosuppressive composition for use in treating immunological disorders |
| AU2017313646A AU2017313646A1 (en) | 2016-08-19 | 2017-08-18 | Immunosuppressive composition for use in treating immunological disorders |
| CN201780062573.9A CN109803681B (en) | 2016-08-19 | 2017-08-18 | Immunosuppressive composition for treating immune disorder |
| US16/326,417 US11491221B2 (en) | 2016-08-19 | 2017-08-18 | Immunosuppressive composition for use in treating immunological disorders |
| SG11201901427RA SG11201901427RA (en) | 2016-08-19 | 2017-08-18 | Immunosuppressive composition for use in treating immunological disorders |
| ES17841766T ES2965448T3 (en) | 2016-08-19 | 2017-08-18 | Immunosuppressive composition comprising an anticytokine antibody and a protein derived from mesenchymal stromal cells for use in the treatment of immunological disorders |
| SG10201906327TA SG10201906327TA (en) | 2016-08-19 | 2017-08-18 | Immunosuppressive composition for use in treating immunological disorders |
| EP17841766.3A EP3500300B1 (en) | 2016-08-19 | 2017-08-18 | Immunosuppressive composition comprising an anti-cytokine antibody and a mesenchymal stromal cell-derived protein for use in treating immunological disorders |
| PCT/SG2017/050408 WO2018034620A1 (en) | 2016-08-19 | 2017-08-18 | Immunosuppressive composition for use in treating immunological disorders |
| US16/282,461 US11246910B2 (en) | 2016-08-19 | 2019-02-22 | Methods of treating immunological disorders using immunosuppressive compositions |
| US18/052,426 US20230181734A1 (en) | 2016-08-19 | 2022-11-03 | Immunosuppressive composition for use in treating immunological disorders |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SG10201606949QA SG10201606949QA (en) | 2016-08-19 | 2016-08-19 | Immunosuppressive composition for use in treating immunological disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201606949QA true SG10201606949QA (en) | 2018-03-28 |
Family
ID=61196933
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201606949QA SG10201606949QA (en) | 2016-08-19 | 2016-08-19 | Immunosuppressive composition for use in treating immunological disorders |
| SG10201906327TA SG10201906327TA (en) | 2016-08-19 | 2017-08-18 | Immunosuppressive composition for use in treating immunological disorders |
| SG11201901427RA SG11201901427RA (en) | 2016-08-19 | 2017-08-18 | Immunosuppressive composition for use in treating immunological disorders |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201906327TA SG10201906327TA (en) | 2016-08-19 | 2017-08-18 | Immunosuppressive composition for use in treating immunological disorders |
| SG11201901427RA SG11201901427RA (en) | 2016-08-19 | 2017-08-18 | Immunosuppressive composition for use in treating immunological disorders |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US11491221B2 (en) |
| EP (1) | EP3500300B1 (en) |
| CN (1) | CN109803681B (en) |
| AU (1) | AU2017313646A1 (en) |
| ES (1) | ES2965448T3 (en) |
| SG (3) | SG10201606949QA (en) |
| WO (1) | WO2018034620A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113896795B (en) * | 2020-12-11 | 2022-07-15 | 广州百暨基因科技有限公司 | anti-CLL1 antibodies and uses thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ249754A (en) * | 1992-03-04 | 1997-06-24 | Schering Corp | Interleukin-10 and its use in inhibiting graft vs host disease or tissue rejection |
| EP1399184A2 (en) | 2000-12-01 | 2004-03-24 | Schering Corporation | Uses of mammalian genes and related reagents |
| PL366451A1 (en) | 2001-04-03 | 2005-02-07 | Societe Des Produits Nestle S.A. | Osteoprotegerin in milk |
| EP1851245B1 (en) | 2005-01-26 | 2012-10-10 | Amgen Fremont Inc. | Antibodies against interleukin-1 beta |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| EP2391651B1 (en) * | 2009-01-28 | 2015-01-21 | The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center | Eotaxin-2 (ccl24) inhibitors in inflammatory, autoimmune, and cardiovascular disorders |
| WO2011072119A2 (en) | 2009-12-10 | 2011-06-16 | The Research Foundation Of State University Of Newyork | Stem-cell material and method of use |
| UY33386A (en) | 2010-05-14 | 2011-12-30 | Abbott Laboratoires | IL-1 UNION PROTEINS |
| CN103857406B (en) * | 2011-06-01 | 2018-02-23 | 吉安特科技公司 | Chemotactic factor (CF) immunoglobulin fused polypeptide, composition and its preparation and application |
| JP6132459B2 (en) | 2011-07-13 | 2017-05-24 | 株式会社 バイオミメティクスシンパシーズ | Prophylactic / therapeutic agent for enteritis containing culture supernatant of mesenchymal stem cells |
| MX2014005570A (en) * | 2011-11-08 | 2014-05-30 | Pfizer | Methods of treating inflammatory disorders using anti-m-csf antibodies. |
| KR101646236B1 (en) | 2014-03-07 | 2016-08-08 | (주)세포바이오 | Composition for suppressing immune response containing proteins derived from mesenchymal stem cell |
-
2016
- 2016-08-19 SG SG10201606949QA patent/SG10201606949QA/en unknown
-
2017
- 2017-08-18 WO PCT/SG2017/050408 patent/WO2018034620A1/en unknown
- 2017-08-18 ES ES17841766T patent/ES2965448T3/en active Active
- 2017-08-18 CN CN201780062573.9A patent/CN109803681B/en active Active
- 2017-08-18 SG SG10201906327TA patent/SG10201906327TA/en unknown
- 2017-08-18 EP EP17841766.3A patent/EP3500300B1/en active Active
- 2017-08-18 AU AU2017313646A patent/AU2017313646A1/en active Pending
- 2017-08-18 SG SG11201901427RA patent/SG11201901427RA/en unknown
- 2017-08-18 US US16/326,417 patent/US11491221B2/en active Active
-
2019
- 2019-02-22 US US16/282,461 patent/US11246910B2/en active Active
-
2022
- 2022-11-03 US US18/052,426 patent/US20230181734A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| SG11201901427RA (en) | 2019-03-28 |
| US20190262424A1 (en) | 2019-08-29 |
| AU2017313646A1 (en) | 2019-02-21 |
| US20210252140A1 (en) | 2021-08-19 |
| EP3500300B1 (en) | 2023-09-27 |
| SG10201906327TA (en) | 2019-08-27 |
| CN109803681A (en) | 2019-05-24 |
| US11246910B2 (en) | 2022-02-15 |
| EP3500300A4 (en) | 2020-03-18 |
| EP3500300A1 (en) | 2019-06-26 |
| US11491221B2 (en) | 2022-11-08 |
| WO2018034620A1 (en) | 2018-02-22 |
| EP3500300C0 (en) | 2023-09-27 |
| US20230181734A1 (en) | 2023-06-15 |
| CN109803681B (en) | 2023-12-12 |
| ES2965448T3 (en) | 2024-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL251721A0 (en) | Compositions and methods for treating cns disorders | |
| HK1250337A1 (en) | Methods and compositions for treating inflammatory and immunological disorders | |
| ME03809B (en) | Compositions and methods for treating cns disorders | |
| PT3224269T (en) | Compositions and methods for treating cns disorders | |
| PT3250210T (en) | Compositions and methods for treating cns disorders | |
| LT3882250T (en) | Tetrahydropyranyl amino-pyrrolopyrimidinone for use in treating btk-mediated disorders | |
| IL250715A0 (en) | Compositions and methods for treating proliferation disorders | |
| IL247699A0 (en) | Compositions and methods for treating kidney disorders | |
| EP3126004A4 (en) | Methods and compositions for treating inflammatory disorders | |
| HUE049518T2 (en) | Compositions and methods for treating and diagnosing ocular disorders | |
| EP3442554A4 (en) | Compositions and methods for treating disorders associated with neovascularization | |
| EP3262065A4 (en) | Methods and compositions for treating dystroglycanopathy disorders | |
| EP3544604A4 (en) | Methods and compositions for treating disorders associated with cortico-hippocampal hyperactivity | |
| SG10201606949QA (en) | Immunosuppressive composition for use in treating immunological disorders | |
| IL262507B (en) | Compositions for use in treating tendon degeneration | |
| PT3420084T (en) | Novel approach for treating inflammatory disorders |